The Future of Virtual Healthcare

A remote patient bio-marker monitoring and clinical decision support platform with Artificial Intelligence

BODY TEMPERATURE

PULSE RATE

RESPIRATION RATE

BLOOD PRESSURE

OXYGEN SATURATION

About MEDIVITALS

Medivitals was established in January 2020 with a vision to progress the development of a AI based clinical decision support platform with high sensitivity and specificity for early detection of diseases. Drawing on a strong background in digital health, telemedicine and health informatics, the company has moved into the early stages of development with a focus on using the latest technology to innovate the future of Virtual Healthcare.

The Medivitals solution will focus on significant opportunities in hospitals, emergency clinics, aged care facilities, remote and rural areas, mining sites and quarantine hotels/homes.   

Product & Software

The Product

Bio-Band

The Medivitals Bio-Band measures 5 vital signs

  • Body temperature
  • Pulse rate
  • Respiration rate (rate of breathing)
  • Blood pressure
  • SpO2 or Oxygen saturation

 

The proposed bio-band device will have  long battery life and use non-allergic material. The bio-band will send all data to a cloud-based data storage using Bluetooth or via an embedded SIM. 

The Software

Medivitals Data, Monitoring and Analysis Platform

These measures are recorded on the Medivitals Data platform where cloud-based software can manage:

  • Disease specific alerts
  • Monitoring
  • Dashboards
  • Analysis
  • Sensor management
  • Actuator Control
  • Configuration Settings

 

The Medivitals Data Analytics platform is used to manage sensor data to monitor and define value-based analytics that can drive better health outcomes for patients.

ADJUNCT PROFESSOR WARREN HARDING

Co-Founder and CEO

Our CEO was the Minister for Health’s nominee on the Western Australian “Sustainable Health Review” which reviewed the next $120bn spend in State funding and recommended significant investment into Care in the Community, digital health, new patient experience and smarter use of data. This allowed Medivitals to position itself in the key role to elevate the importance of digital health in transforming health services.

PROFESSOR YOGESAN KANAGASINGAM

Co-Founder and CIO

Through its Chief Innovation Officer, Medivitals boasts considerable experience in developing and deploying medical diagnostic devices from bench to bedside with history of a patent portfolio of over 35 patents. One of these devices, EyeScan,  for diagnosing anterior segment and retinal diseases, is used by NASA at the International Space Station and many eye clinics in USA and Europe.

INNOVATING & INVESTING IN THE FUTURE OF VIRTUAL HEALTHCARE

Hospitals

One device for continuous monitoring of multiple vital signs.

Emergency Clinics

Replace bulky devices currently used for manual measurement of vital signs 

Aged Care Facilities

Continuous monitoring of vital signs, activity monitoring and falls detection

Remote & Rural Areas

Comprehensive telemedicine consultations with access to biomarkers for evidence based care delivery.

Mining Sites

Continuous monitoring of biomarkers from mining staff for flu like symptoms and other diseases.

Home & Hotel Quarantine

Continuous vital sign and movement monitoring to alert medical staff on deteriorating patients.

INVEST IN THE FUTURE

Get in touch to receive a prospectus for the Medivital’s entry into the AI driven Software Platform.